Application deadline: 01 February 2021 - now closed. Applications for 2022 will be advertised Autumn 2021.
How to apply
Please contact us for application forms and conditions and guidelines
Tel: 01293 762009
Please complete and sign your application form and return to: Jackie Shuttlewood, The Novo Nordisk UK Research Foundation, 3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA or electronically via email to email@example.com
Application form: National or international
meeting (click to download)
(If you experience any issues dowloading these forms please contact the Foundation Administrator)
Who can apply?
Applicants for a Fund award must be a qualified health care
professional living and working in the UK. A qualified health care
professional is a person requiring a qualification or license to
practice in the UK (such as nurses, dieticians, podiatrists and
pharmacists) except GMC registered professionals (who are not eligible
to apply for this award).
The objective of the Fund is to support clinical projects, training and education within the field of diabetes mellitus in the UK. Funding is considered under the following:
N.B. No retrospective awards will
Attendance at a national or international meeting - For those applicants wishing to attend a national/international meeting it is preferred that they have submitted an abstract or presentation to the meeting. Preference will be given to those applicants.
Clinical Project - Applications for funding of a
clinical project must be clearly itemised by the applicant and must
directly relate to project costs such as stationary, postage, room
or equipment hire, patient travel. Expenses such as transcription
costs for qualitative work in respect of a study gaining a higher
degree, and ‘participant thank you gifts such as vouchers etc.’ are
not usually considered to be appropriate funding awards by the committee.
The annual amount
available for the Fund is decided by the Trustees each year.
A selection committee will recommend applicants and the final decision for funding is granted by the Board of Trustees. Decisions are reached by simple majority.
Trustees expect all award
recipients to adhere to regulations, and where appropriate the
research governance framework.
The funds are granted for
the purpose stated in the notification from the Board and the amount
granted is, unless agreed otherwise, fixed on the basis of the
application. If the recipient wishes to use the funds in a way that
differs substantially from the application, permission from the
Board should be obtained in advance. If the full amount of the Fund
is not used, the balance must be returned to the Foundation.
On completion of the
project, course or meeting, a maximum 400 word report must be
submitted to the Board including an account of how the funds have
been used and how the recipient, their practice and their patients
have benefited. For Clinical Projects a peer reviewed abstract or
publication would be accepted.
In publications appearing
as a result of any project, acknowledgement should be made to the
support provided by The Novo Nordisk UK Research Foundation.
Further details can be
found in the Policies and Guidelines of the Foundation, available on
the Foundation website, which should be referred to in addition to
Due to the number of
applications received and the time demands placed on reviewers,
unfortunately, it is not possible to provide feedback to each
All enquiries should be
directed and applications submitted to: Jackie Shuttlewood, The Novo
Nordisk UK Research Foundation, 3 City Place, Beehive Ring Road,
Gatwick, RH6 0PA
Tel: 01293 762009 or 07764 958938
Unsuccessful applications will be deleted from our records 12 months after a decision on funding is received.
The sole sponsor of The Novo
Nordisk UK Research Foundation is Novo Nordisk Ltd